Research Article

Correlation of plasma protein from MDS, young and elderly patients by SDS-page

Nathanielly de Lima Silva, Danilo Nobre, Josiel Nascimento dos Santos, Márcia Santos Rezende, Lúcio Henrique Sousa Pinheiro, Carlos Arthur Cardoso Almeida and Dulce Marta Schimieguel*

Published: 11/11/2019 | Volume 2 - Issue 1 | Pages: 087-088

Abstract

Summary: Myelodysplastic Syndrome (MDS) is a heterogeneous group of clonal hematopoietic malignancies characterized by progressive cytopenias, ineffective hematopoiesis, bone marrow hypercellularity and transformation to acute myeloid leukemia (AML).

Objectives: Identify plasma proteins from MDS patients and from two healthy controls groups (young and elderly) by SDS-Page.

Methods: Plasma from 08 healthy young, 08 healthy elderly and 08 MDS patients were used for this study. Proteins were fractionated, precipitated, used for SDS-PAGE gel analysis, stained with comassie brilliant blue, scanned and bands were analyzed.

Results: It was possible to identify in both, 20% fraction and supernatant, proteins that were differentially expressed in each group. The ones that have showed some clinical relevance. Fibronectin was highly expressed only in the young control group. α2-Macroglobulin was also expressed in both control groups, but it was not expressed in the MDS group. Haptoglobin was highly expressed only in the elderly control and SMD groups.

Conclusion: Protein expression in plasma can be a biomarker for MDS, and may play a key role in the process of aging and hematologic malignancies development.

Read Full Article HTML DOI: 10.29328/journal.ijbmr.1001009 Cite this Article

References

  1. Mueller BU, Seipel K, Pabst T. Myelodysplastic syndromes and acute myeloid leukemias in the elderly. Eur J Intern Med. 2018; 58: 28-32. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30527920
  2. DeZern AE, Malcovati L, Ebert BL. CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice. Am Soc Clin Oncol Educ Book. 2019; 39: 400-410. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31099654
  3. Zini G. Diagnostics and Prognostication of Myelodysplastic Syndromes. Ann Lab Med. 2017; 37: 465-474. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28840983
  4. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122: 3616-3627. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24030381
  5. Saha S, Halder S, Bhattacharya D, Banerjee D, Chakrabarti A. Fractional Precipitation of Plasma Proteome by Ammonium Sulphate: Case Studies in Leukemia and Thalassemia. J Proteomics Bioinformatics. 2012; 5.
  6. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry. 1976; 72: 248-254. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/942051